Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 05, 2025 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference

All CDI-988 doses, ranging from 100 mg to 1200 mg, in the Phase 1 study were well toleratedCompany expects to initiate Phase 1b study with CDI-988 in norovirus-infected healthy subjects later this...